Haemonetics Corp. (HAE) Misses Q2 EPS Views; Affirms Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.40 +0.74%
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.65, $0.13 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $170.6 million versus the consensus estimate of $170.4 million.
Affirms outlook.
Affirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades Haemonetics to Buy, raises price target to $123
- Ally CFO: Still Expecting To Deliver In Range Of NIM Guidance - Bloomberg
- Yeti outlines growth targets and financial framework through 2030
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
